Technology | EP Mapping and Imaging Systems
Acutus Medical announced that the U.S. Food and Drug Administration (FDA) has cleared the AcQMap High Resolution Imaging and Mapping System and the AcQMap 3-D Imaging and Mapping Catheter for use in patients for whom electrophysiology procedures have been prescribed. The company plans to introduce initial commercial systems to U.S. customers in early 2018.
October 24, 2017
News | Embolic Protection Devices
October 23, 2017 — Claret Medical announced that it has closed on a Series C financing of $14.5 million led by ...
October 23, 2017
News | Atrial Fibrillation
October 23, 2017 — University of North Carolina (UNC) School of Medicine cardiologist Anil Gehi, M.D., will use a $1.7 ...
October 23, 2017Sponsored Content
Feature | Information Technology
Providing exceptional cardiovascular care for patients to achieve the best possible outcomes is the number one goal for ...
March 21, 2024
Videos | Heart Valve Technology
A discussion with Mario Goessl, M.D., Ph.D., director of research and education at the Minneapolis Heart Institute. He ...
October 23, 2017
News | Heart Valve Technology
October 23, 2017 — The first patient implant has taken place in the APOLLO Trial, the pivotal trial designed to evaluate ...
October 23, 2017
Technology | Implantable Cardiac Monitor (ICM)
October 23, 2017 – The U.S. Food and Drug Administration (FDA) has cleared Abbott’s Confirm Rx Insertable Cardiac ...
October 23, 2017Sponsored Content
Feature | Cardiac Imaging
Cardiac positron emission tomography (PET) is growing in popularity among cardiologists because it provides the ability ...
March 05, 2024
News | Cardiac Diagnostics
The American Heart Association, Verily and AstraZeneca announced the opening of the One Brave Idea Science Innovation Center in Boston. The Center will be home to the Cardiovascular Medicine Innovation team, led by Calum MacRae, M.D., Ph.D., chief of cardiovascular medicine at Brigham and Women’s Hospital (BWH) who, leveraging the latest technologies and scientific advances, will continue their work for One Brave Idea, the $75 million research enterprise charged with bringing an end to coronary heart disease and its consequences.
October 20, 2017
News | Heart Failure
October 20, 2017 — Boston Scientific announced new data from the Multisensor Chronic Evaluation in Ambulatory Heart ...
October 20, 2017
News | Womens Cardiovascular Health
Nonalcoholic fatty liver disease (NAFLD) is associated with significantly higher risk of subsequent cardiovascular events in women, but not in men, according to research presented at The Liver Meeting held by the American Association for the Study of Liver Diseases.
October 20, 2017Sponsored Content
Blog
When performing radiofrequency (RF) ablation to treat cardiac arrhythmia, medical professionals must balance the safety ...
December 11, 2023
News | Advanced Visualization
October 20, 2017 — Digital health company Analytics 4 Life announced it has completed a $25 million Series B financing ...
October 20, 2017
News | Patient Engagement
October 19, 2017 — Novel smartphone and tablet applications for atrial fibrillation patients and healthcare ...
October 19, 2017
News | Womens Cardiovascular Health
African American women were found to be twice as likely to be diagnosed with peripartum cardiomyopathy as compared to women of Caucasian, Hispanic/Latina, Asian and other ethnic backgrounds, according to a new study. The study, the largest of its kind, was published in JAMA Cardiology by researchers from the Perelman school of Medicine at the University of Pennsylvania.
October 19, 2017Sponsored Content
Case Study | Hemodynamic Monitoring Systems
Change Healthcare Cardiology Hemodynamics is an integrated hemodynamic monitoring system for monitoring vital signs and ...
November 14, 2023
News | Endovascular Aortic Repair
Endologix Inc. received Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration (FDA) to commence a confirmatory clinical study evaluating the safety and effectiveness of the Nellix EndoVascular Aneurysm Sealing System (EVAS) for the endovascular treatment of infrarenal abdominal aortic aneurysms. The EVAS2 IDE Multicenter Safety and Effectiveness Confirmatory Study (EVAS2) will prospectively evaluate the refined Indications for Use (IFU) and the Nellix Gen2 EVAS System.
October 19, 2017
Feature | Cardiac Diagnostics | Nanette H. Bishopric, M.D., FACC, FAHA
A new area of DNA testing involving telomere length may enhance a patient’s cardiovascular disease risk stratification ...
October 19, 2017
Technology | Heart Failure
October 18, 2017 — The U.S. Food and Drug Administration (FDA) recently approved a new treatment option for patients who ...
October 18, 2017© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now